Tarsus Pharmaceuticals opened higher at $76.81, compared with its previous close of $76.76. In the last trading session, the stock traded between $74.91 and $77.88. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Tarsus Pharmaceuticals is now worth
$ 279.70
Giving a profit of
$ 179.70 (179.70%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.13 (+0.17%)
Day High
$77.88
Day Low
$74.91
Day Open
$76.81
Prev Close
$76.76
Volume
3,32,111
1W Return
11.40%
1M Return
3.36%
3M Return
10.71%
6M Return
28.90%
1Y Return
1.65%
Fundamentals
Market Cap ($ Mn)
3,791
PE Ratio
-
PB Ratio
8.96
PEG Ratio
-
ROE
-21.04%
ROCE
-18.31%
EPS (TTM)
$-13.56
Investment Returns
1 Week
11.40%
1 Month
3.36%
3 Months
10.71%
6 Months
28.90%
9 Months
17.59%
Financials
Quarterly
All values in $ Mn
78.3
Mar 25
102.7
Jun 25
118.7
Sep 25
151.7
Dec 25
173.9
Jun 26
194.6
Sep 26
Updates
4Nov
Tarsus Pharmaceuticals Q3FY26 Results: EPS beats estimate, sales up 64%
Adjusted loss per share of $(0.78) beat analyst estimate of $(2.73). Net product sales rose 64% YoY to $194.6 million, exceeding estimates. Full-year 2026 sales guidance raised to $715-$730 million. Losses decreased 160% YoY from $(0.30) per share in prior year period.
9 days ago
14Oct
Tarsus Pharmaceuticals files prospectus for 2.91 million share resale
Tarsus Pharmaceuticals Inc filed a prospectus with the SEC. The filing covers the resale of up to 2.91 million common shares. The offer is made by selling stockholders, not the company.
1mo ago
16Sep
Barclays reinstates Overweight on Tarsus Pharmaceuticals with $110 target
Barclays reinstates Overweight rating on Tarsus Pharmaceuticals. Analyst Glen Santangelo sets a new price target of $110. The move signals renewed bullish sentiment from the broker.
1mo ago
2Sep
Tarsus Pharmaceuticals to attend Wells Fargo, H.C. Wainwright investor conferences
Tarsus Pharmaceuticals management to attend Wells Fargo Healthcare Conference on September 8. Company plans fireside chat at H.C. Wainwright Global Investment Conference on September 15. Live webcasts and replays available on Tarsus website within 48 hours. Pipeline includes FDA-approved XDEMVY and Phase 2 candidates TP-04, TP-05, and IRX-101.
Tarsus Pharmaceuticals reported Q2 EPS of $(0.43), missing estimates by 115%, while sales of $173.912 million beat expectations by 2.50% and rose 69.41% YoY. The results highlight strong top-line growth offset by wider-than-expected losses per share compared to the prior year's $(0.48).
3mo ago
6Aug
Tarsus acquires Alkeus for Stargardt therapy, priced $125M PIPE
Tarsus Pharmaceuticals acquires Alkeus Pharmaceuticals to add gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease, to its pipeline. The company priced a $125M PIPE at $56/share to fund the acquisition and support clinical development, closing August 7, 2026.
